[Diagnosis of diabetic cardiac autonomic neuropathy]

Type 1 diabetes silent heart attack

Share Link

The main characteristics of general metabolic disturbances resulting in increased risk for cardiovascular morbidity in diabetes mellitus are disputed. The importance of early detection of these complications screening and its therapeutic consequences are emphasized.

  1. Gora nyárfa és a cukorbetegség kezelésében
  2.  Мисс Флетчер.
  3. Készítmények kezelésére lábak során cukorbetegség

Hazards of sulfanylurea therapy and near-normoglycemic metabolic control especially in elderly patients are briefly discussed. The Framingham Study. Circulation Diabetologia Ten years mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycemic controls and risk indices for coronary heart disease in borderline diabetics.

N Eng J Med Diabetes, other risk factors and 12 years cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care Knowles, HC: Coronary artery disease in diabetes.

Its developements, course and response to treatment [in: Zoneirach, S, ed.

 У нас ничего такого не случалось. - Вот.  - Она едва заметно подмигнула.

Thomas, Sprinfield, Illinois, Ceriello, A: Coagulation activation in diabetes mellitus: the type 1 diabetes silent heart attack of hyperglycaemia and therapeutic prospects. Editorial: Hypertriglyceridaemia and vascular risk.

CAN is strongly associated with increased mortality, and in some studies with morbidity of vascular complications, such as stroke, coronary artery disease and myocardial infarction. At the early stages, CAN can be subclinical and it becomes clinically evident as the disease progresses. Subclinically, the disease is defined by cardiovascular reflex testing, which may have prognostic implications. Clinically, the impairment in autonomic function is associated with resting tachycardia, exercise intolerance, orthostatic hypotension, syncope, intraoperative cardiovascular instability, silent myocardial infarction and ischemia, and increased mortality.

Lancet Damsgaard, EM, Froland, A, Jorgensen, OD, Mogensen, CE: Prognostic value of urinary albumin excretion rate and other risk factors in elderly diabetic patients and non-diabetic control subjects surviving the first 5 years after assessment. Diabetologia Am J Med 90 Suppl.

type 1 diabetes silent heart attack

Am J Cardiol Jensen, T, Borch-Johnsen, K, Kofoed-Enevoldsen, A, Deckert, T: Coronary heart disease in young Type 1 insulindependent diabetic patients with and without diabetic nephropathy: incidence and risk factors.

Clements, RS: Diabetic complications and the role of aldose reductase inhibition.

MeSH terms

Am J Med Nathan, DM: Long-term complications of diabetes mellitus. Med Clin North Am Diabetes Curr Op Cardiol 6: Lorenzi, M, Cagliero, E: Pathobiology of endothelial and other vascular cells in diabetes mellitus: call for data. Henry, PD: Atherogenesis, calcium and calcium antagonists. J Am Coll Cardiol Romics L, Brooser G: Early retinai vascular signs in hyperlipoproteinaemia. Acta Med Acad Sci Hung Lancet I: Diabetes Care 8: A follow-up study in diabetic patients.

Acta Cardiol Brussels Dzau, VJ: Molecular and physiological aspects of tissue renin-angiotensin system: emphasis on cardiovascular control.

type 1 diabetes silent heart attack

J Hypertens 6: S7-S12, Diabetologia Hungarica 1: The Diabetes Control and Tacrolimus ointment Trial Research Group: The effect of intensive treatment of diabeles on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

N Engl J Med Drugs Exptl Clin Res Factors in development of diabetic neuropathy: baseline analysis of neuropathy in feasibility phase of the Diabetes Control and Complications Trial DCCT.

Hofman, D, Opie, LH: Potassium chanel blockade and acute myocardial infarction: implication for management of noninsulin requiring diabetic patient.

type 1 diabetes silent heart attack

Eur Heart J Magy Belorv Arch Orv Hetil Dzau JV: Short- and long-term determinants of cardiovascular function and therapy: contributions of circulation and tissue renin-angiotensin systems. J Cardiovasc Pharmacol S1-S5,